MALVERN, Pa. and SHANGHAI, Feb. 23 /PRNewswire/ -- Frontage Laboratories Inc. ("Frontage"), a leading high quality provider of bioanalytical, pre-clinical, clinical and drug development services to global pharmaceutical companies, is pleased to announce it has expanded its research and development agreement with Beijing Second Pharmaceuticals, the ethical drug division of Beijing Pharmaceutical Group ("Beijing Pharma"), to accelerate Beijing Pharma's entrance into the international generic drug market. In addition, Frontage recently hired Len Stigliano as Chief Financial Officer and Derek (Yuanchao) Zhang, Ph.D. as Vice President of Regulatory Affairs and Clinical Pharmacology. These investments further strengthen Frontage's market leadership as a U.S.-China contract research organization.
The agreement with Beijing Pharmaceuticals is a further expansion of Frontage's current relationship with this client and its overall business in China. As part of the agreement, Frontage will obtain a newly constructed, 1,800 sq.meter R&D center and continued access to Beijing Pharma's GMP manufacturing areas. Frontage will also collaborate with Beijing Pharma to develop 12 ANDA products over the next 3-5 years, which will be marketed in China, Europe and the U.S. Frontage has been operating in China for 3 years, and serves both global and Chinese pharmaceutical customers. In 2007, Frontage helped Beijing Pharma in designing, renovating, and commissioning its manufacturing facilities to meet U.S. FDA and ICH GMP requirements, in building its GMP systems, employee training and in product development efforts. One of the products developed through the relationship has been filed to the U.S. FDA in 2008, with several more targeted for filing in 2009. European authorities successfully inspected the facilities in 2008.
"This partnership demonstrates our continued commitment to support the U.S., European and Chinese companies' development programs in generic drugs, and to help them gain access to international markets," said Song Li, President and CEO of Frontage. "We are pleased that the investments we have made in our business over the last year are being recognized by our customers and partners."
As further evidence of the company's growth, Frontage recently hired Len Stigliano as CFO and Derek Zhang as VP of Regulatory Affairs and Clinical Pharmacology. Stigliano, a 25 year financial professional in the life sciences business was most recently the CFO of Novavax, a publicly traded novel vaccine development company. Dr. Zhang brings to Frontage over 10 years of combined experience in the areas of drug research, development and regulatory approval, including four years of experience at Pfizer and six years of regulatory experience at the U.S. Food and Drug Administration.
"We are extremely pleased to welcome Len and Derek to Frontage," said Brett Tucker, Partner with Baird Capital Partners Asia, an investor in Frontage. "Len brings a broad base of financial experience and global expertise to Frontage, and Derek brings a solid reputation among the regulatory and clinical pharmacology community in the U.S. and China. These investments will only help us serve our global customer base better."
Biography - Len Stigliano
Stigliano has over 25 years of experience and proven success at publicly traded healthcare and life sciences companies both as a senior operating and financial executive. He has been instrumental in driving revenues, growth, drug development, profitability and operational performance at each of these companies, including a leading contract research organization during its high growth phase. Stigliano was most recently Chief Financial Officer of Novavax, a publicly traded novel vaccine development company. Prior to that he held various senior financial and operating roles within Omnicare Clinical Research, Inc., where he was eventually responsible for global operations of over $145 million of annual revenue. At Omnicare he also oversaw over 800 employees worldwide, and implemented new systems and processes for the company's global drug development operations, including the oversight of all clinical trials, project management, and project profitability. He is a Certified Public Accountant, received his BA from
Biography - Dr. Derek Zhang
Dr. Zhang has 10 years of combined experience in the areas of drug research, development and regulatory approval, including four years of industrial experience at Pfizer and six years of regulatory experience at U.S. FDA. Derek was Senior Clinical Pharmacology Reviewer in the Office of Clinical Pharmacology, the Center for Drug Evaluation and Research, the Food and Drug Administration. He successfully reviewed numerous NDAs (including several NME NDAs and BLAs), NDA supplements, and IND submissions. He also contributed to several guidance document development and revision. His specific areas of expertise include clinical pharmacology, biopharmaceutics and regulatory sciences, and he has extensive experience in clinical pharmacology drug development plans/strategies and regulatory requirements. Derek received his Ph.D. from the
About Frontage Laboratories, Inc.
Frontage Laboratories, Inc. is a rapidly expanding global pharmaceutical R&D services company with offices in the U.S., Europe and China. Frontage provides research services to facilitate pharmaceutical discovery, development, preclinical and clinical research, commercialization and product launch, and assists its clients to resolve complex product development issues with a strong, experienced management team. The company's clients include four of the top ten largest pharmaceutical companies in the world. Frontage is experienced with developing new chemical entities, generic equivalent products, and supporting research for large molecules. For more information, please contact us at email@example.com or visit us at www.frontagelab.com
|SOURCE Frontage Laboratories, Inc.|
Copyright©2009 PR Newswire.
All rights reserved